down arrow

Hepion Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4268973025
USD
0.06
-0.02 (-24.75%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.060.06

52 Week

0.0336.73
Valuation
Technical
Day's Volume

CASH

4.49 k

Shareholding (Mar 2025)

FII

0.12%

Held by 6 FIIs

DII

97.33%

Held by 3 DIIs

Promoter

0.00%

How big is Hepion Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Hepion Pharmaceuticals, Inc. has a market capitalization of 0.89 million, with net sales of 0.00 million and a consolidated net profit of -16.46 million. Shareholder's funds were reported at -1.86 million, and total assets stood at 1.61 million.

As of Jun 18, Hepion Pharmaceuticals, Inc. has a market capitalization of 0.89 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -16.46 million.<BR><BR>As of Dec 24, the shareholder's funds were reported at -1.86 million, and total assets stood at 1.61 million.

Read More

What does Hepion Pharmaceuticals, Inc. do?

22-Jun-2025

Hepion Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. It operates as a micro-cap company with a market cap of $0.89 million and reported a net profit loss of $6 million as of March 2025.

Overview: <BR>Hepion Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing targeted therapies for liver diseases, specifically non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 0.89 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -412.85% <BR>Price to Book: 0.23 <BR><BR>Contact Details: <BR>Address: 399 Thornall St, EDISON NJ: 08837-2236 <BR>Tel: ['1 732 9024000', '1 646 2743580'] <BR>Fax: 1 732 9024100 <BR>Website: http://contravir.com/

Read More

Who are in the management team of Hepion Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Hepion Pharmaceuticals, Inc. includes Dr. Gary Jacob (Chairman), Dr. Robert Foster (CEO and Chief Scientific Officer), and several independent directors: Dr. Thomas Adams, Dr. Timothy Block, Mr. John Brancaccio, Dr. Arnold Lippa, and Dr. Peter Wijngaard. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Hepion Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Gary Jacob, Chairman of the Board<BR>- Dr. Robert Foster, Chief Executive Officer, Chief Scientific Officer, and Director<BR>- Dr. Thomas Adams, Independent Director<BR>- Dr. Timothy Block, Independent Director<BR>- Mr. John Brancaccio, Independent Director<BR>- Dr. Arnold Lippa, Independent Director<BR>- Dr. Peter Wijngaard, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Hepion Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of March 18, 2025, Hepion Pharmaceuticals has a mildly bearish technical trend, with mixed signals from various indicators, and has significantly underperformed the S&P 500 with a year-to-date return of -99.76%.

As of 18 March 2025, the technical trend for Hepion Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the Bollinger Bands show a bearish trend on the monthly timeframe. Daily moving averages are mildly bearish, and the KST is mildly bullish weekly but bearish monthly. The OBV shows a mildly bullish trend on the monthly timeframe, with no clear trend indicated by Dow Theory.<BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.76% compared to the S&P 500's 12.22%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.67

stock-summary
Return on Equity

-423.63%

stock-summary
Price to Book

0.21

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.79%
0%
-8.79%
6 Months
49.01%
0%
49.01%
1 Year
-99.8%
0%
-99.8%
2 Years
-99.96%
0%
-99.96%
3 Years
-84.17%
0%
-84.17%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

Hepion Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Hepion Pharmaceuticals, Inc. technically bullish or bearish?

As of 18 March 2025, the technical trend for Hepion Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the Bollinger Bands show a bearish trend on the monthly timeframe. Daily moving averages are mildly bearish, and the KST is mildly bullish weekly but bearish monthly. The OBV shows a mildly bullish trend on the monthly timeframe, with no clear trend indicated by Dow Theory. In terms of performance, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.76% compared to the S&P 500's 12.22%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-21.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0
Tax Ratio
20.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.16
EV to EBIT
0.18
EV to EBITDA
0.18
EV to Capital Employed
3.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1934.66%
ROE (Latest)
-412.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (2.55%)

Foreign Institutions

Held by 6 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 74.36% vs 72.34% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "-8.50",
          "chgp": "84.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "4.50",
          "chgp": "-93.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-3.90",
          "chgp": "74.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 73.01% vs -15.88% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.30",
          "val2": "-45.20",
          "chgp": "57.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.40",
          "val2": "-4.10",
          "chgp": "207.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-48.90",
          "chgp": "73.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.30
-8.50
84.71%
Interest
0.00
0.00
Exceptional Items
0.30
4.50
-93.33%
Consolidate Net Profit
-1.00
-3.90
74.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 74.36% vs 72.34% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.30
-45.20
57.30%
Interest
1.20
0.00
Exceptional Items
4.40
-4.10
207.32%
Consolidate Net Profit
-13.20
-48.90
73.01%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 73.01% vs -15.88% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Hepion Pharmaceuticals, Inc. stock-summary
stock-summary
Hepion Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.
Company Coordinates stock-summary
Company Details
399 Thornall St , EDISON NJ : 08837-2236
stock-summary
Tel: 1 732 90240001 646 2743580
stock-summary
http://contravir.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."